Company intelligence / Profile preview

PeriRx

Marple/Broomall, Pennsylvania, United Statesjennyswisher.com ↗

Ownership: Private
Development stage: Commercial

Overview

PeriRx has launched SaliMark OSCC, a clinically validated, non-invasive salivary DNA biomarker test for early detection of oral squamous cell carcinoma. The test is based on NIH-funded research and has been validated in large clinical trials in collaboration with leading academic centers. Additional pipeline products target early detection of lung cancer, diabetes, periodontal disease, and Sjögren's syndrome.

Therapeutic areas: OncologyEndocrinologyRheumatologyOther
Modalities: DeviceMolecular diagnostic testDNA biomarker assay
Industry: Molecular Diagnostics

Partnerships

University of California at Los Angeles (UCLA) [technology licensor]National Cancer Institute [clinical validation partner]University of Michigan, Michigan State University, Providence Health System Detroit [academic collaborators]

Beyond the preview

Go deeper on PeriRx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PeriRx.

Explore the full profile